| Gene information | Literature | Expression | lncRNA | Mutation | Homolog |
Basic Information | |
|---|---|
Gene ID | 128869 |
Name | PIGU |
Synonymous | phosphatidylinositol glycan anchor biosynthesis, class U;PIGU;phosphatidylinositol glycan anchor biosynthesis, class U |
Definition | CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1|GPI transamidase component PIG-U|GPI transamidase subunit|cell division cycle 91-like 1 protein|cell division cycle protein 91-like 1|phosphatidylinositol glycan anchor biosynthesis class U pro |
Position | 20q11.22 |
Gene type | protein-coding |
Title | Abstract |
| CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. | Genomic amplification at 20q11-13 is a common event in human cancers. We isolated a germline translocation breakpoint at 20q11 from a bladder cancer patient. We identified CDC91L1, the gene encoding CDC91L1 (also called phosphatidylinositol glycan class U (PIG-U), a transamidase complex unit in the glycosylphosphatidylinositol (GPI) anchoring pathway), as the only gene whose expression was affected by the translocation. CDC91L1 was amplified and overexpressed in about one-third of bladder cancer cell lines and primary tumors, as well as in oncogenic uroepithelial cells transformed with human papillomavirus (HPV) E7. Forced overexpression of CDC91L1 malignantly transformed NIH3T3 cells in vitro and in vivo. Overexpression of CDC91L1 also resulted in upregulation of the urokinase receptor (uPAR), a GPI-anchored protein, and in turn increased STAT-3 phosphorylation in bladder cancer cells. Our findings suggest that CDC91L1 is an oncogene in bladder cancer, and implicate the GPI anchoring system as a potential oncogenic pathway and therapeutic target in human cancers. |